GOUTIFADE 80MG 20TAB ; febuxostat, antigout agents
GOUTIFADE 80MG 20TAB
ACTIVE-INGREDIENT OF GOUTIFADE 80MG 20TAB
each goutifade 80 mg film coated tablet contains 80 mg of febuxostat .
goutifade is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout .
Goutifade is not recommended for the treatment of asymptomatic hyperuricemia
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
recommended dose : for the treatment of hyperuricemia in patients with gout , goutifade , febuxostat is recommendedat 40 mg or 80 mg once daily .
The recommended starting dose of goutifade , febuxostat is 40 mg once daily . F
or patients who do not achieve a serum uric acid (sUA) less than 6 mg /dl after two weeks with 40 mg , goutifade 80 mg , febuxostat is recommended . goutifade , febuxostat can be taken without regard to food or antacid use . special populations : no dose adjustment is necessary when administering goutifade , febuxostat in patients with mild to moderate renal impairment . the recommended starting dose of goutifade , febuxostat is 40 mg once daily .
for patients who do not achieve a sUA less than 6 mg/dl after two weeks with 40 mg , goutifade 80 mg , febuxostat is recommended . no dose adjustment is necessary in patients with mild to moderate hepatic impairment . uric acid level: testing for the target serum uric acid level of less than 6 mg/dl may be performed as early as two weeks after initiating goutifade therapy .
gout flares : gout flares may occur after initiation of goutifade due to changing serum acid levels resulting in mobilization of urate from tissue deposits .
if a gout flare occurs during goutifade treatment , goutifade need not be discontinued .
Before starting to use the medicine, that is, any medicine, or the pharmacist
Cancer in medicine before using this medicine
hypersensitiviity to the active substance or to any of the excipients .
Febuxostat is contraindicated in patients receiving azathioprine
Store at temperature not exceeding 30°C, in dry place.
carton box containing 2 or 3 (white opaque aclar/pvc/al) strips of 10 film coated tablets & an inner leaflet .
GLOBAL NAPI PHARMACEUTICALS